Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Psychotic Mood Disorders Clear all
Recruiting Phase 4 Interventional

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT07105111
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Bryant, Arkansas • Chino, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness

NCT02663349
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Psychotic Disorders
Interventions
Social Cognition and Intervention Training
Behavioral
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients

NCT03751488
View directory record Official record
Conditions
Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder
Interventions
LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Garden Grove, California • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 28, 2026, 10:22 PM EDT
Withdrawn No phase listed Observational

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

NCT06328140
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions
Lurasidone, FDA Approved antidepressant treatment
Drug
Lead sponsor
George West Mental Health Foundation d/b/a Skyland Trail
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 28, 2026, 10:22 PM EDT
Withdrawn Phase 4 Interventional

Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole

NCT01155544
View directory record Official record
Conditions
Substance Abuse, Substance Dependence
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
16 Years to 44 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Glen Oaks, New York • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

NCT00303602
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Escondido, California • Garden Grove, California • National City, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Sep 28, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Pregnant and Postpartum Women With and Without Mood Disorders

NCT03615794
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Postpartum Depression, Postpartum Psychosis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

PTSD (PostTraumatic Stress Disorder) Services for Veterans With SMI (Severe Mental Illness)

NCT01542229
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions
Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU), Treatment As Usual (TAU)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2019 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 4 Interventional

Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine

NCT01153490
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Behavioral Intervention
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Glen Oaks, New York • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness

NCT05660070
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Mood Disorder, Psychotic
Interventions
mobile Social Interaction Therapy by Exposure (mSITE)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 28, 2026, 10:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations

NCT02149823
View directory record Official record
Conditions
Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD, Autism Spectrum Disorder, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo
Drug
Lead sponsor
Maria de las Mercedes Perez Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

NCT03872596
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 3 Interventional

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

NCT00363376
View directory record Official record
Conditions
Weight Gain
Interventions
Zonisamide, olanzapine, Sugar Pill (placebo)
Drug
Lead sponsor
Lindner Center of HOPE
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Sep 28, 2026, 10:22 PM EDT
Recruiting Not applicable Interventional

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

NCT06221852
View directory record Official record
Conditions
Bipolar I Disorder, Psychosis, Schizoaffective Disorder
Interventions
Ketogenic diet, Dietary Guidelines for Americans
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 28, 2026, 10:22 PM EDT
Recruiting Phase 1Phase 2 Interventional

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

NCT03794076
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
Cromoglycate, Placebo
Drug
Lead sponsor
Vishwajit Nimgaonkar, MD PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 28, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Psychotic Major Depression With Mifepristone

NCT00867360
View directory record Official record
Conditions
Affective Disorders, Psychotic, Depressive Disorder
Interventions
Mifepristone (RU-486), Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 28, 2026, 10:22 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Risk State for Bipolar Disorder in Adolescents

NCT01383915
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 18 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 28, 2026, 10:22 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
View directory record Official record
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness

NCT02029989
View directory record Official record
Conditions
Hyperlipidemia, Diabetes, Hypertension
Interventions
Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 64 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional Results available

Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)

NCT01992393
View directory record Official record
Conditions
Epilepsy, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depression
Interventions
TIME
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Phase 4 Interventional Results available

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.

NCT03156504
View directory record Official record
Conditions
Major Depression, Bipolar I Disorder, Bipolar II Disorder, Unipolar Depression
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Ann Arbor, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness

NCT02421965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Interventions
FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Sep 28, 2026, 10:22 PM EDT
Completed Not applicable Interventional

Mobile Enhancement of Motivation in Schizophrenia

NCT03059771
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Psychosis
Interventions
Mobile Enhancement of Motivation (MEMS), Control
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 28, 2026, 10:22 PM EDT